CMPS COMPASS Pathways (CMPS) Q2 FY26 earnings call
COMPASS Pathways reported a strong second quarter, highlighted by highly statistically significant Phase III data for COMP360, which has largely de-risked its clinical and regulatory profile for Treatment-Resistant Depression. The company is on track to complete its NDA filing in Q4 FY26, with commercial preparations well underway for an anticipated H1 2027 launch. While regulatory and reimbursement timelines remain fluid, management expressed confidence in the blockbuster potential of COMP360 and its ability to fundamentally change mental health care.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.